Conference Coverage
Conference Coverage
Early MS biomarkers may improve prediction of long-term outcomes
Combining two biomarkers may shed more light on MS prognosis.
Conference Coverage
Real-world data support safety of newer LAA device
More than 18 months after approval, the Watchman FLX left atrial appendage closure device is performing well at 45 days in real-world use.
Conference Coverage
B-cell depletion overkill?
B-cell depletion following ocrelizumab or rituximab treatment often lasts longer than 6 months.
Conference Coverage
Home cognitive therapy looks feasible in MS
A randomized trial demonstrates how to deliver therapy at home.
Conference Coverage
DMTs tied to lower MS relapse during reproductive therapy
The likelihood of achieving pregnancy through assisted reproductive technologies while having MS appeared favorable.
Conference Coverage
MRI biomarker to be tested in MS
A new prospective trial aims to prove that central vein sign can distinguish MS from clinical mimics.
Conference Coverage
Early menopause, early dementia risk, study suggests
Early menopause is linked to an increased risk of presenile dementia before age 65 years in a large study, suggesting the need for close...
Conference Coverage
Ozanimod shows long-term safety, despite a pandemic
Open-label study confirms efficacy and COVID-19–related safety.
Latest News
‘Robust’ increase in tics during the pandemic explained?
Approximately 85% of teens surveyed said their tic frequency worsened during COVID.
Conference Coverage
Self-care tips for clinicians as COVID-19 lingers
“We want to promote psychological flexibility: the ability to stay in contact with the present moment,” Dr. Jon A. Levenson said.
Conference Coverage
B-cell therapy for MS may impact COVID-19 vaccination
A prospective study found improved neutralizing antibody response with more time elapsed since therapy and vaccination.